世界におけるOX-40アゴニストのパイプライン分析2015

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DELV51103)
◆英語タイトル:OX-40 Agonist -Pipeline Insights, 2015
◆発行会社/調査会社:DelveInsight
◆商品コード:DELV51103
◆発行日:42248
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆ページ数:※お問い合わせください。
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single User USD675 ⇒換算¥76,275見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD1,350 ⇒換算¥152,550見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[世界におけるOX-40アゴニストのパイプライン分析2015]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Summary
DelveInsight’s, OX-40 Antagonist- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the OX-40 Antagonist. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The OX-40 AgonistReport helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, OX-40 Antagonist-Pipeline Insights, 2015 Report covers the OX-40 Antagonistpipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides OX-40 Agonistrelated therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for OX-40 Antagonist.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the Mechanism of Action (MoA).


Scope
- DelveInsight’s report provides a OX-40 Agonist Landscape across the globe
- The report provides drug profiles which includes product description, licensors & collaborators, development partner and chemical information
- Coverage of the OX-40 Agonist pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for OX-40 Agonistand also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


*** レポート目次(コンテンツ)***

• OX-40 AgonistOverview
• OX-40 AgonistDisease Associated
• OX-40 AgonistPipeline Therapeutics
• OX-40 AgonistTherapeutics under Development by Companies
• OX-40 AgonistLate Stage Products (Filed and Phase III)
• Comparative Analysis
• OX-40 AgonistMid Clinical Stage Products (Phase II)
• Comparative Analysis
• OX-40 Agonist Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• OX-40 AgonistDiscovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• OX-40 Antagonist– Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• OX-40 Antagonist– Discontinued Products
• OX-40 Agonist– Dormant Products
• Companies Involved in Therapeutics Development for OX-40 Antagonist
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for OX-40 Agonistby Therapy Area, 2015
• Number of Products under Development for OX-40 Antagonist,2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• OX-40 AgonistAssessment by Monotherapy Products
• OX-40 AgonistAssessment by Combination Products
• OX-40 AgonistAssessment by Route of Administration
• OX-40 AgonistAssessment by Stage and Route of Administration
• OX-40 AntagonistAssessment by Molecule Type
• OX-40 AgonistAssessment by Stage and Molecule Type
• OX-40 AgonistTherapeutics – Discontinued Products
• OX-40 AgonistTherapeutics – Dormant Products
• Products under Development by Companies, 2015

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DELV51103 )"世界におけるOX-40アゴニストのパイプライン分析2015" (英文:OX-40 Agonist -Pipeline Insights, 2015)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。